Oragenics
OGEN
24 hedge funds and large institutions have $6.82M invested in Oragenics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 0 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
41% more funds holding
Funds holding: 17 → 24 (+7)
3% more capital invested
Capital invested by funds: $6.63M → $6.82M (+$189K)
0% more ownership
Funds ownership: 0% → 0.01% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$431K |
| 2 |
VF
Virtu Financial
New York
|
+$130K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$110K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$90.5K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$53.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.03K |
OGEN Hedge Fund Activity: Q3 2021 in Review
24 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q3 2021, worth a combined $6.82M — up 2.8% from $6.63M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new OGEN positions and 0 closed out — a net gain of 7 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $431K. The largest seller was Millennium Management, cutting an estimated $6.03K.
- 24 institutional investors held Oragenics (OGEN) as of Q3 2021, up from 17 in Q2 2021.
- Funds reported $6.82M of Oragenics stock for Q3 2021, up 2.8% quarter-over-quarter.
- 7 funds opened new Oragenics positions in Q3 2021 and 0 closed out, a net change of +7 holders.
- The largest Oragenics buyer in Q3 2021 was Renaissance Technologies, an estimated $431K added.
- The largest Oragenics seller in Q3 2021 was Millennium Management, an estimated $6.03K sold.
Based on aggregated 13F filings for Q3 2021.